Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
30
A dietary supplement provided as powder dissolved in a glass of water
A dietary supplement provided as powder dissolved in a glass of water
Applied Bioenergetics Lab at Faculty of Sport and PE
Novi Sad, Vojvodina, Serbia
Change in muscular strength
Baseline vs. 6 months
Time frame: Baseline vs. 6 months post-intervention
Change in muscle mass
Baseline vs. 6 months
Time frame: Baseline vs. 6 months post-intervention
Change in muscle metabolites evaluated with MR spectroscopy
Baseline vs. 6 months
Time frame: Baseline vs. 6 months post-intervention
Change in cognitive performance evaluated with Mini-Mental State Exam test
Baseline vs. 6 months
Time frame: Baseline vs. 6 months post-intervention
Change in serum creatine
Baseline vs. 6 months
Time frame: Baseline vs. 6 months post-intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.